As Immuno-oncology (I-O) continues to play a more relevant role in cancer treatment, overcoming challenges related to the development of immunotherapies becomes increasingly important. Developing I-O trials requires thoughtful planning. Download ICON’s latest white paper to read about:
- True Progression & Response Assessment – Apply the most comprehensive markers to assess true efficacy of an immunotherapy
- Safety Management – Balance antitumour immunity and immunetoxicity with a customised safety management programme
- Current I-O Market – Overcome challenges in balancing patient, physician, and payer perspectives
- The Future of I-O – Learn more about promising developments in I-O including checkpoint inhibitors and CAR-T cells.